ShiraTronics: A New Dawn for Chronic Migraine Sufferers
October 15, 2024, 9:32 pm
Location: United States, Minnesota, Minneapolis
Employees: 11-50
Total raised: $102M
Chronic migraines are like shadows that loom over millions, darkening their days and stealing their joy. For those who suffer, the search for relief can feel like an endless journey through a fog. Enter ShiraTronics, a beacon of hope in this landscape. Recently, the clinical-stage medical device company announced a significant milestone: a $66 million Series B financing round. This funding is not just a number; it represents a lifeline for countless individuals grappling with debilitating migraines.
ShiraTronics is on a mission to develop neurostimulation therapies specifically designed for chronic migraine patients. The latest funding round was led by Norwest Venture Partners, with participation from a host of other investors, including Seroba, OSF Ventures, and the Global BioAccess Fund. This financial backing will propel the company forward as it embarks on its pivotal trial, the RELIEV-CM2 Clinical Study, which has received FDA approval. This trial is crucial. It aims to evaluate the safety and effectiveness of the ShiraTronics Migraine Therapy System in patients who have not found relief through conventional treatments.
Chronic migraine is a formidable foe. It affects approximately 5 to 6 million people in the U.S. alone. These individuals endure 15 or more headache days each month, with at least eight of those days marked by the intense symptoms of a migraine. For about 3 million of these patients, existing therapies fall short. They are treatment-resistant, left to navigate their lives in darkness, often confined to quiet rooms, seeking solace from the pain.
The urgency for effective treatment options is palpable. A recent study by the National Headache Foundation revealed that over half of chronic migraine patients are dissatisfied with their current therapies. Many have abandoned systemic drugs due to adverse side effects. Current medications often provide minimal relief, reducing headache days by just two per month on average. This is a drop in the ocean for those who suffer daily.
ShiraTronics is stepping into this void with a drug-free solution. The company’s Migraine Therapy System is a minimally invasive device implanted beneath the skin of the head. It delivers small electrical pulses to targeted nerves associated with migraine pain. This innovative approach aims to disrupt the pain signals that wreak havoc on patients' lives. Imagine a gentle wave washing over a stormy sea, calming the chaos within.
What sets ShiraTronics apart is not just its technology but also its patient-centric approach. The therapy allows patients to personalize and control their treatment through a dedicated application. This feature empowers users, giving them the tools to manage their condition continuously, 24/7. It’s like having a lighthouse guiding them through the darkest nights.
The company has already garnered attention from the FDA, receiving Breakthrough Device designation in 2021. This recognition underscores the potential of the ShiraTronics Migraine Therapy System. In a recent pilot study, the device demonstrated promising results, showing significant improvements in quality-of-life scores and reductions in headache days and severity of migraine attacks. These findings are not just numbers; they represent real lives transformed.
ShiraTronics is not just a company; it’s a movement. It aims to change the narrative for chronic migraine sufferers. With the recent funding, the company is poised to advance its clinical trials and seek premarket approval from the FDA. The goal is clear: to bring this groundbreaking therapy to market and provide relief to millions who have long been trapped in a cycle of pain.
The journey of ShiraTronics is a testament to innovation and resilience. Co-founders Lynn Elliott and Mudit K. Jain have laid a strong foundation, and under the leadership of CEO Rob Binney, the company is ready to take the next steps. Their vision is to serve millions of chronic migraine patients globally, offering them a chance at a better quality of life.
As the world watches, ShiraTronics stands at the forefront of a revolution in migraine treatment. The company’s commitment to developing state-of-the-art neurostimulation solutions is commendable. With each passing day, they inch closer to delivering hope to those who have long felt abandoned by traditional medicine.
In conclusion, ShiraTronics is more than just a medical device company. It embodies hope, innovation, and the relentless pursuit of relief for chronic migraine sufferers. As they embark on this critical phase of their journey, the stakes are high, but so is the potential for change. For millions, the dawn of a new era in migraine treatment may finally be on the horizon.
ShiraTronics is on a mission to develop neurostimulation therapies specifically designed for chronic migraine patients. The latest funding round was led by Norwest Venture Partners, with participation from a host of other investors, including Seroba, OSF Ventures, and the Global BioAccess Fund. This financial backing will propel the company forward as it embarks on its pivotal trial, the RELIEV-CM2 Clinical Study, which has received FDA approval. This trial is crucial. It aims to evaluate the safety and effectiveness of the ShiraTronics Migraine Therapy System in patients who have not found relief through conventional treatments.
Chronic migraine is a formidable foe. It affects approximately 5 to 6 million people in the U.S. alone. These individuals endure 15 or more headache days each month, with at least eight of those days marked by the intense symptoms of a migraine. For about 3 million of these patients, existing therapies fall short. They are treatment-resistant, left to navigate their lives in darkness, often confined to quiet rooms, seeking solace from the pain.
The urgency for effective treatment options is palpable. A recent study by the National Headache Foundation revealed that over half of chronic migraine patients are dissatisfied with their current therapies. Many have abandoned systemic drugs due to adverse side effects. Current medications often provide minimal relief, reducing headache days by just two per month on average. This is a drop in the ocean for those who suffer daily.
ShiraTronics is stepping into this void with a drug-free solution. The company’s Migraine Therapy System is a minimally invasive device implanted beneath the skin of the head. It delivers small electrical pulses to targeted nerves associated with migraine pain. This innovative approach aims to disrupt the pain signals that wreak havoc on patients' lives. Imagine a gentle wave washing over a stormy sea, calming the chaos within.
What sets ShiraTronics apart is not just its technology but also its patient-centric approach. The therapy allows patients to personalize and control their treatment through a dedicated application. This feature empowers users, giving them the tools to manage their condition continuously, 24/7. It’s like having a lighthouse guiding them through the darkest nights.
The company has already garnered attention from the FDA, receiving Breakthrough Device designation in 2021. This recognition underscores the potential of the ShiraTronics Migraine Therapy System. In a recent pilot study, the device demonstrated promising results, showing significant improvements in quality-of-life scores and reductions in headache days and severity of migraine attacks. These findings are not just numbers; they represent real lives transformed.
ShiraTronics is not just a company; it’s a movement. It aims to change the narrative for chronic migraine sufferers. With the recent funding, the company is poised to advance its clinical trials and seek premarket approval from the FDA. The goal is clear: to bring this groundbreaking therapy to market and provide relief to millions who have long been trapped in a cycle of pain.
The journey of ShiraTronics is a testament to innovation and resilience. Co-founders Lynn Elliott and Mudit K. Jain have laid a strong foundation, and under the leadership of CEO Rob Binney, the company is ready to take the next steps. Their vision is to serve millions of chronic migraine patients globally, offering them a chance at a better quality of life.
As the world watches, ShiraTronics stands at the forefront of a revolution in migraine treatment. The company’s commitment to developing state-of-the-art neurostimulation solutions is commendable. With each passing day, they inch closer to delivering hope to those who have long felt abandoned by traditional medicine.
In conclusion, ShiraTronics is more than just a medical device company. It embodies hope, innovation, and the relentless pursuit of relief for chronic migraine sufferers. As they embark on this critical phase of their journey, the stakes are high, but so is the potential for change. For millions, the dawn of a new era in migraine treatment may finally be on the horizon.